Stephen Dilly, Sierra Oncology CEO
January 25, 2022 07:00 AM ESTUpdated 07:14 AM
R&D

Claim­ing a win where Gilead failed, Sier­ra touts PhI­II suc­cess in a JAK in­hibitor — and is ready to take it to the FDA

Max Gelman

Senior Editor

About three and a half years ago, Sier­ra On­col­o­gy took on a for­mer­ly failed JAK in­hibitor can­di­date from Gilead, be­liev­ing it could suc­ceed where the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times